{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:10:09Z","timestamp":1789013409093,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>T cell\u2013mediated rejection significantly constrains the success of organ transplantation. T-cell activation relies on the complementary CD28 and ICOS costimulatory pathways. Thus, this research assessed a new dual CD28\/ICOS antagonist, acazicolcept, in rigorous allogeneic transplantation models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>Mouse models for allogeneic skin transplantation and abdominal heterotopic heart transplantation were developed. Recipients received acazicolcept, PBS, FK506, or single-pathway antagonists (belatacept or prezalumab). Graft viability, histopathological analysis, and T-cell infiltration were evaluated. Flow cytometry assessed spleen and blood lymphocyte subsets and costimulatory molecules. Donor-specific antibodies and graft C4d deposition were assessed to evaluate humoral responses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Acazicolcept significantly extended the median survival time of skin and heart allografts to 31 d and 42.5 d, respectively, substantially surpassing other groups and mitigated histopathological damage. Mechanistic investigations demonstrated that the drug simultaneously downregulated the surface expression of CD28 and ICOS on T cells; effectively inhibited the development of effector memory T cells (Tem); and reduced the expression of PD-1 and CD69, reflecting a profound attenuation of early T-cell activation. Moreover, acazicolcept markedly inhibited humoral immune responses, as demonstrated by diminished C4d deposition in grafts and lowered levels of donor-specific antibody-IgG\/IgM in peripheral blood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Acazicolcept exhibits robust, superior antirejection efficacy compared with single-pathway blockades by concurrently inhibiting CD28 and ICOS signals. This dual mechanism effectively suppresses T-cell activation, effector memory differentiation, and the subsequent antibody\u2013mediated response, offering a robust preclinical justification for its clinical advancement in solid organ transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/tp.0000000000005897","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:01:16Z","timestamp":1789012876000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Study on the Antirejection Effects of the Dual ICOS and CD28 Antagonist Acazicolcept (ALPN-101) in Mouse Skin and Heart Transplantation Models"],"prefix":"10.1097","author":[{"given":"Leigang","family":"Guo","sequence":"first","affiliation":[{"name":"First Central Hospital of Tianjin Medical University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojingnan","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ma","sequence":"additional","affiliation":[{"name":"Biological Sample Resource Sharing Center, Tianjin First Central Hospital, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[{"name":"Organ Transplantation Research Center, Tianjin First Central Hospital, Tianjin, China."},{"name":"Institute of Transplantation Medicine Nankai University, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaojuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Organ Transplantation Research Center, Tianjin First Central Hospital, Tianjin, China."},{"name":"Institute of Transplantation Medicine Nankai University, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxi","family":"Wang","sequence":"additional","affiliation":[{"name":"Organ Transplantation Research Center, Tianjin First Central Hospital, Tianjin, China."},{"name":"Institute of Transplantation Medicine Nankai University, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panpan","family":"Zhan","sequence":"additional","affiliation":[{"name":"Organ Transplantation Research Center, Tianjin First Central Hospital, Tianjin, China."},{"name":"Institute of Transplantation Medicine Nankai University, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyang","family":"Shen","sequence":"additional","affiliation":[{"name":"School of Medicine, Nankai University, Tianjin, China."},{"name":"Organ Transplantation Research Center, Tianjin First Central Hospital, Tianjin, China."},{"name":"Institute of Transplantation Medicine Nankai University, Nankai University, Tianjin, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"R1-20260910","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/s41591-025-03801-9","article-title":"Reshaping transplantation with AI, emerging technologies and xenotransplantation.","volume":"31","author":"Loupy","year":"2025","journal-title":"Nat Med"},{"key":"R2-20260910","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","article-title":"Mechanism of cellular rejection in transplantation.","volume":"25","author":"Ingulli","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"R3-20260910","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nri1245","article-title":"T-cell-antigen recognition and the immunological synapse.","volume":"3","author":"Huppa","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"R4-20260910","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 Costimulation: from mechanism to therapy.","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"R5-20260910","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition.","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"R6-20260910","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-065X.2009.00781.x","article-title":"Costimulatory pathways in transplantation: challenges and new developments.","volume":"229","author":"Li","year":"2009","journal-title":"Immunol Rev"},{"key":"R7-20260910","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2174\/156652406779010812","article-title":"Costimulatory molecules as targets for the induction of transplantation tolerance.","volume":"6","author":"Alegre","year":"2006","journal-title":"Curr Mol Med"},{"key":"R8-20260910","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14728222.2014.863875","article-title":"Targeting CD28 to prevent transplant rejection.","volume":"18","author":"Yeung","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"R9-20260910","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2004-04-1596","article-title":"The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation.","volume":"105","author":"Riley","year":"2005","journal-title":"Blood"},{"key":"R10-20260910","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2016.02.004","article-title":"CD28 costimulatory signals in T lymphocyte activation: Emerging functions beyond a qualitative and quantitative support to TCR signalling.","volume":"28","author":"Porciello","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"R11-20260910","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/ajt.16218","article-title":"CTLA4-Ig prolongs graft survival specifically in young but not old mice.","volume":"21","author":"Heinbokel","year":"2021","journal-title":"Am J Transplant"},{"key":"R12-20260910","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/87880","article-title":"Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28-\/- mice.","volume":"7","author":"Maier","year":"2001","journal-title":"Nat Med"},{"key":"R13-20260910","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/00007890-200003150-00040","article-title":"Absence of host B7 expression is sufficient for long-term murine vascularized heart allograft survival.","volume":"69","author":"Szot","year":"2000","journal-title":"Transplantation"},{"key":"R14-20260910","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay4799","article-title":"ICOSL+ Plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS\/CD28 antagonist.","volume":"12","author":"Adom","year":"2020","journal-title":"Sci Transl Med"},{"key":"R15-20260910","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nri1131","article-title":"Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling.","volume":"3","author":"Rudd","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"R16-20260910","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2009.119164","article-title":"Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1\/T helper 17 cells and mitigates autoimmune arthritis.","volume":"69","author":"Frey","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"R17-20260910","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.coi.2010.01.001","article-title":"Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS).","volume":"22","author":"Simpson","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"R18-20260910","doi-asserted-by":"crossref","first-page":"100713","DOI":"10.1016\/j.trre.2022.100713","article-title":"Inducible Co-Stimulator (ICOS) in transplantation: a review.","volume":"36","author":"Hodgson","year":"2022","journal-title":"Transplant Rev (Orlando)"},{"key":"R19-20260910","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13075-021-02709-2","article-title":"Acazicolcept (ALPN-101), a dual ICOS\/CD28 antagonist, demonstrates efficacy in systemic sclerosis preclinical mouse models.","volume":"24","author":"Orvain","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R20-20260910","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/art.40479","article-title":"Brief report: a randomized, double-blind, parallel-group, placebo-controlled, multiple-dose study to evaluate AMG 557 in patients with systemic lupus erythematosus and active lupus arthritis.","volume":"70","author":"Cheng","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"R21-20260910","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/art.42484","article-title":"Non-redundant roles of T cell costimulation pathways in inflammatory arthritis revealed by dual blockade of ICOS and CD28 with Acazicolcept (ALPN-101).","volume":"75","author":"Dillon","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"R22-20260910","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/tvst.12.3.27","article-title":"Systemic administration of Acazicolcept, a dual CD28 and inducible T cell Costimulator inhibitor, Ameliorates experimental autoimmune uveitis.","volume":"12","author":"Wilson","year":"2023","journal-title":"Transl Vis Sci Technol"},{"key":"R23-20260910","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/cts.12983","article-title":"First-in-human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN-101, a dual CD28\/ICOS antagonist, in healthy adult subjects.","volume":"14","author":"Yang","year":"2021","journal-title":"Clin Transl Sci"},{"key":"R24-20260910","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adh0085","article-title":"Targeted depletion of PD-1-expressing cells induces immune tolerance through peripheral clonal deletion.","volume":"9","author":"Cui","year":"2024","journal-title":"Sci Immunol"},{"key":"R25-20260910","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature12058","article-title":"Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility.","volume":"496","author":"Xu","year":"2013","journal-title":"Nature"},{"key":"R26-20260910","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature13803","article-title":"T-B-cell entanglement and ICOSL-driven feed-forward regulation of germinal centre reaction.","volume":"517","author":"Liu","year":"2015","journal-title":"Nature"},{"key":"R27-20260910","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35051113","article-title":"ICOS is essential for effective T-helper-cell responses.","volume":"409","author":"Tafuri","year":"2001","journal-title":"Nature"},{"key":"R28-20260910","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/eji.200636661","article-title":"The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells.","volume":"37","author":"Mahajan","year":"2007","journal-title":"Eur J Immunol"},{"key":"R29-20260910","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1172\/JCI200317008","article-title":"The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity.","volume":"112","author":"Harada","year":"2003","journal-title":"J Clin Invest"},{"key":"R30-20260910","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline.","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"R31-20260910","doi-asserted-by":"crossref","first-page":"969633","DOI":"10.3389\/fimmu.2022.969633","article-title":"Costimulation blockade and Tregs in solid organ transplantation.","volume":"13","author":"Muckenhuber","year":"2022","journal-title":"Front Immunol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:01:22Z","timestamp":1789012882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0000000000005897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000005897","relation":{},"ISSN":["0041-1337","1534-6080"],"issn-type":[{"value":"0041-1337","type":"print"},{"value":"1534-6080","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}